Clinical trials: Aspergillus Infection
Allergic Bronchopulmonary Aspergillosis
A Prospective Study on Optimizing Treatment for ABPA
This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.
- Trial name
- NCT05129033
- Testing
- Prednisone tablet, itraconazole, Omalizumab
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Aspergillus Infections, Candida Infections
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
- Conditions
- Aspergillus Infections, Candida Infections, Fungal Infections
- Trial name
- NCT02631954
- Testing
- Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Invasive Fungal Infections
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
- Trial name
- NCT05491733
- Testing
- APX001, APX001A
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Healthy
Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects
This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of Voriconazole Inhalation Powder versus…
- Trial name
- NCT04872231
- Testing
- Voriconazole Inhalation Powder
- Where
- Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- TFF Pharmaceuticals, Inc.
Environmental Exposure, Asthma
Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis
This study is a prospective, observational study of patients aged 18-80 years with clinical diagnosis of bronchial asthma, allergic bronchopulmonary aspergillosis (ABPA), bronchiectasis and healthy subjects.
- Conditions
- Environmental Exposure, Asthma, Bronchiectasis, ABPA
- Trial name
- NCT07313904
- Where
- China
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Cystic Fibrosis
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
This study is designed to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics (proof of concept) of QBW251 in healthy subjects and cystic fibrosis patients following single and multiple doses.
- Trial name
- NCT02190604
- Testing
- QBW251
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs.
- Trial name
- ABPA (NCT00585364)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Opportunistic Fungal Infection, Opportunistic Viral Infection
T Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus Fumigatus Infections After Allogeneic Stem Cell Transplantation
The purpose of the study is to determine the feasibility, safety and efficacy of administering rapidly-generated donor-derived pentavalent-specific T cells (Penta-STs) to mediate antiviral and antifungal activity in hematopoietic…
- Conditions
- Opportunistic Fungal Infection, Opportunistic Viral Infection, Bone Marrow Transplant Infection
- Trial name
- Penta-STs-001 (NCT05471661)
- Testing
- Pentavalent-specific T cells (penta-STs)
- Where
- 2 sites in Greece
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- George Papanicolaou Hospital
Invasive Aspergillosis
Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole
To evaluate the drug-drug interaction between rifampicin and voriconazole according to CYP2C19 genotype quantitatively following a single oral administration of 200 mg voriconazole
- Trial name
- NCT01080651
- Testing
- Voriconazole
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Allergic Bronchopulmonary Aspergillosis (ABPA)
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and…
- Trial name
- NCT07040332
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD)
Immune Status and Disease Control of Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked…
- Conditions
- Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
- Trial name
- ISDC-IAD (NCT07493629)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
Pulmonary Invasive Aspergillosis
Application of an Electronic Nose in the Early Detection of ASpergillosis
The purpose of this study is to establish the accuracy with which the eNose can discriminate patients with invasive pulmonary aspergillosis from controls.
- Trial name
- AENEAS (NCT01395446)
- Where
- Netherlands
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Invasive Aspergillosis
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Double blind, placebo controlled, ascending multiple (10) oral dose, sequential group study. Twenty-four subjects will complete the study in 3 cohorts (Groups A to C), each group consisting of 8 subjects.
- Trial name
- ORALMAD (NCT02737371)
- Testing
- F901318 Dose level A oral, F901318 Dose level B oral, F901318 Dose level C oral
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
F901318 Multiple Ascending Dose Study
Double blind, placebo controlled, parallel group ascending dose study evaluating single and multiple (x8 days) dose levels of F901318 in groups of male healthy subjects with the objective of defining a dosing schedule for phase…
- Trial name
- NCT02342574
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
Study of Potential for Interaction of Fluconazole With F901318
This will be an open label study in two parts. In the first part, F901318 (dose 2 mg/kg IV over 4 hours, Day 1) will be followed by F901318 (2 mg/kg IV over 4 hours) given on Day 8, after dosing with fluconazole 800 mg daily for…
- Trial name
- NCT02730442
- Testing
- F901318, Fluconazole
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
Single Ascending Oral Dose Study of F901318
Double blind, placebo controlled, ascending single oral dose, sequential group study. Forty subjects will complete the study in 5 cohorts (Groups A to E), each group consisting of 8 subjects.
- Trial name
- NCT02394483
- Testing
- F901318 safety, F901318 tolerability, F901318 pharmacokinetics
- Where
- United Kingdom
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis
Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples
Multicentre, diagnostic study evaluating the performance of an aspergillus-specific PCR in cerebrospinal fluid samples of immunocompromised patients for identification of central nervous system aspergillosis.
- Trial name
- NCT01614145
- Where
- 3 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Aspergillosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945
- Trial name
- NCT02715570
- Testing
- PC945 - single doses, PC945 - repeat doses
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pulmocide Ltd